BioSpace News Archive

Novotech has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting.

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024.

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent business highlights.

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets.

Teva Pharmaceutical Industries Ltd. announced that Richard Francis, Teva’s President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024.

Epredia and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer.

Soleno Therapeutics, Inc. announced the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share.

Remix Therapeutics announced the first patients enrolled and dosed in two Phase 1 clinical trials assessing REM-422, a first-in-class MYB mRNA degrader, as a potential treatment for recurrent or metastatic adenoid cystic carcinoma and acute myeloid leukemia/high-risk myelodysplastic syndromes.

Geron Corporation reported financial results and business highlights for the first quarter 2024.

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.